Insmed Incorporated INSM
Composite 44/100; the shares have moved about 75% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 18/100 — a strong mark against it.
Growth ranks 96/100 — a strong point in its favour. Balance-sheet strength ranks 65/100 — a moderate point in its favour.
Quality ranks 18/100 — a strong mark against it. Valuation ranks 22/100 — a strong mark against it. Momentum ranks 32/100 — a moderate mark against it.
What the company does Insmed develops therapies for rare and serious diseases, including ARIKAYCE for refractory nontuberculous mycobacterial lung infections and brensocatib for bronchiectasis. Its pipeline also includes treprostinil palmitil for pulmonary hypertension and INS1201 for gene therapy in phase 1.
Key financials Gross margin is 81.8%, but operating and net margins are negative at -65.5% and -144.4%, respectively. ROE is -294.5%, ROA -31.1%, and ROCE -64.2%. Revenue grew 229.6%, while EPS growth is 0.0%.
Stock health The stock is down -24.84% over 3 months and -34.90% over 6 months, with RSI at 38.40. The Piotroski F-Score is 5/9, and the Altman Z-score is 5.08, indicating moderate financial stress.
Price vs fair value Insmed trades at a PREMIUM of 8.30% to our fair-value estimate of 93.02. - Commercial acceleration efforts are noted despite Q1 challenges (Insider Monkey). - Expected to beat Q2 earnings estimates (Zacks). - Highlighted among biotech stocks for Q2 earnings potential (Zacks). - Recent momentum remains weak, with a -52.30% drawdown from its 52-week high.
Looking forward Forward P/E is 16.37, but valuation metrics like P/B (31.71) and negative EV/EBITDA (-6.05) reflect high uncertainty. Analysts see a potential discount of 93.30% to a 12-month target of 196.18 (analyst count 22.0).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.